MedTrace Logo

ATV/Ritonavir Nevirapine Interaction (USPAC)

NCT00162149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2011-04-08

No results posted yet for this study

Summary

Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in HIV-infected individuals.

Conditions

  • HIV Infections

Interventions

DRUG

Nevirapine

Tablets, Oral, 200 mg, Twice daily, 3 days.

DRUG

Nevirapine + Atazanavir/Ritonavir

Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.

DRUG

Nevirapine + Atazanavir/Ritonavir

Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.

DRUG

Atazanavir + Ritonavir

Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162149 on ClinicalTrials.gov